MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 04-25-2026
Akari Therapeutics, Plc Cash and Cash Equivalents 2011-2026 | AKTX
Annual Cash and Cash Equivalents Akari Therapeutics, Plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 2.6 M | 3.84 M | 13.2 M | - | 14.1 M | 5.73 M | 5.45 M | 28.1 M | 34.1 M | 68.9 M | 3.33 M | 554 K | 1.1 M | 6 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 68.9 M | 6 K | 13.9 M |
Quarterly Cash and Cash Equivalents Akari Therapeutics, Plc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.48 M | 2.71 M | 2.58 M | 2.6 M | 2.25 M | 4.18 M | 1.31 M | 3.84 M | 4.73 M | 7.18 M | 11.6 M | - | - | - | - | 9.36 M | - | 3.79 M | - | 14.1 M | 12.3 M | 12.7 M | 7.82 M | 5.73 M | 6.27 M | 2.74 M | 6.15 M | 5.45 M | - | 15.1 M | - | 28.1 M | - | 30.1 M | - | 34.1 M | - | 9.66 M | 61.4 M | 68.9 M | 78.8 M | 201 K | 68.9 M | 3.33 M | 3.33 M | 6.22 M | 6.22 M | 554 K | - | - | - | 1.1 M | - | - | - | 6 K | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 78.8 M | 6 K | 14 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
3.06 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M |  China |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
Midatech Pharma plc
MTP
|
8.53 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
AlloVir
ALVR
|
98.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Aptorum Group Limited
APM
|
3.5 M | $ 0.88 | -1.69 % | $ 6.47 M | China |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B | France |
 |
Aquestive Therapeutics
AQST
|
121 M | $ 4.1 | 1.23 % | $ 438 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
320 M | $ 22.45 | 1.13 % | $ 3.72 B | USA |
 |
Athira Pharma
ATHA
|
69.3 M | - | - | $ 269 M | USA |
 |
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
5.71 B | - | - | $ 96.9 B | Britain |
 |
Atreca
BCEL
|
30.8 M | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
86.5 M | - | -7.31 % | $ 87 M | USA |
 |
Calithera Biosciences
CALA
|
59.5 M | - | -10.95 % | $ 876 K | USA |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
CymaBay Therapeutics
CBAY
|
207 M | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
50 M | - | - | $ 3.74 B | USA |
 |
Cerus Corporation
CERS
|
20 M | $ 2.03 | 5.73 % | $ 387 M | USA |
 |
Caladrius Biosciences
CLBS
|
16.2 M | - | -16.75 % | $ 25.8 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
50.7 M | - | - | $ 231 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
7.36 M | $ 13.64 | 9.82 % | $ 1.81 B |  Australia |
 |
Aeterna Zentaris
AEZS
|
7.31 M | - | 5.93 % | $ 314 M |  Canada |
 |
BioNTech SE
BNTX
|
7.68 B | $ 103.45 | 1.85 % | $ 27.2 B | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
29 K | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
83.5 M | - | - | $ 2.18 B | USA |
 |
AIkido Pharma
AIKI
|
34 M | - | 1.93 % | $ 17.4 M | USA |
 |
Innate Pharma S.A.
IPHA
|
28.1 M | $ 1.44 | -3.36 % | $ 235 M | France |
 |
Dynavax Technologies Corporation
DVAX
|
95.9 M | - | - | $ 2.02 B | USA |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
66.4 M | - | - | $ 28.6 M | USA |
 |
Editas Medicine
EDIT
|
147 M | $ 3.0 | 6.38 % | $ 266 M | USA |
 |
Edesa Biotech
EDSA
|
1 M | $ 18.27 | 14.94 % | $ 58.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
8.27 M | $ 3.19 | 6.69 % | $ 5.25 M | Israel |
 |
Eiger BioPharmaceuticals
EIGR
|
25.4 M | - | -9.21 % | $ 2.55 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
19.2 M | - | -5.68 % | $ 8.28 M | USA |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Ampio Pharmaceuticals
AMPE
|
4.09 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Therapeutics
APLT
|
49.9 M | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
935 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
56.2 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
53.7 M | - | -13.39 % | $ 1.45 M | USA |